All In Biotech

Drug Trial Radar · NCT04546724

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Pivotal Study To Evaluate Safety And Immunogenicity Of A Live-Attenuated Chikungunya Virus Vaccine Candidate In Adults Aged 18 Years And Above

Last checked: Nov 19, 2026Latest source record: Jun 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". Randomized with 4,128 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,128

Actual

Start

Sep 17, 2020

Primary completion

May 19, 2021

Study completion Oct 15, 2021

Sponsor

Lead sponsor
Valneva Austria GmbHIndustry
Sponsor type
Industry
First posted
Sep 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This was a prospective, randomized, double-blinded, multicenter, pivotal clinical study evaluating the final dose of VLA1553 (1 x10E4 TCID50 per dose) in comparison to a placebo control. The final dose of VLA1553 or control was administered as single immunization on Day 1. Overall, 4.128 male and female subjects aged 18 years and above were randomized into the study.

Conditions

  • Chikungunya Virus Infection

Interventions

  • VLA1553Biological

    Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose

  • PlaceboBiological

    Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With a Seroprotective CHIKV Antibody Level for Baseline Negative Subjects 28 Days Post-vaccinationTime frame: on Day 29 after single vaccination

Locations

44 sites in 1 country. Site status is shown where the registry gives one.

  • Accelerated Enrollment Solutions (AES)

    Chandler, Arizona

  • Accelerated Enrollment Solutions (AES)

    Phoenix, Arizona

  • Alliance for Multispecialty Research (AMR)

    Tempe, Arizona

  • ELITE Research Network (ELITE)

    Little Rock, Arkansas

  • Velocity Clinical Research, Chula Vista

    Chula Vista, California

  • Accelerated Enrollment Solutions (AES)

    San Diego, California

  • Accel Research Sites - DeLand

    DeLand, Florida

  • ELITE Research Network (ELITE)

    Hallandale, Florida

  • Meridien Research - Maitland

    Maitland, Florida

  • Accelerated Enrollment Solutions (AES)

    Melbourne, Florida

  • Suncoast Research Group, LLC

    Miami, Florida

  • ELITE Research Network (ELITE)

    North Miami Beach, Florida

  • Jacksonville Center for Clinical Research, LTD dba St. Johns Center for Clinical Research

    Ponte Vedra, Florida

  • Synexus - The Villages

    The Villages, Florida

  • ELITE Research Network (ELITE)

    Meridian, Idaho

  • Accelerated Enrollment Solutions (AES)

    Chicago, Illinois

  • Accelerated Enrollment Solutions (AES)

    Peoria, Illinois

  • Alliance for Multispecialty Research (AMR)

    El Dorado, Kansas

  • Alliance for Multispecialty Research (AMR)

    Newton, Kansas

  • Alliance for Multispecialty Research (AMR)

    Wichita, Kansas

  • Alliance for Multispecialty Research (AMR)

    Lexington, Kentucky

  • AMR - New Orleans - Center for Clinical Research

    New Orleans, Louisiana

  • Alliance for Multispecialty Research (AMR)

    Kansas City, Missouri

  • Meridian Clinical Research - Grand Island

    Grand Island, Nebraska

  • Platinum Research Network (Platinum)

    Omaha, Nebraska

  • Accelerated Enrollment Solutions (AES)

    Omaha, Nebraska

  • Alliance for Multispecialty Research (AMR)

    Las Vegas, Nevada

  • Meridian Clinical Research

    Endwell, New York

  • Rochester Clinical Research

    Rochester, New York

  • Lucas Research

    Morehead City, North Carolina

  • ELITE Research Network (ELITE)

    Wilmington, North Carolina

  • Accelerated Enrollment Solutions (AES)

    Cincinnati, Ohio

  • ELITE Research Network (ELITE)

    Oklahoma City, Oklahoma

  • Velocity Clinical Research - Medford

    Medford, Oregon

  • Synexus - Anderson

    Anderson, South Carolina

  • Vitalink Research - Anderson

    Anderson, South Carolina

  • Alliance for Multispecialty Research (AMR)

    Knoxville, Tennessee

  • Tekton Research - Beaumont

    Beaumont, Texas

  • PanAmerican Clinical Research - US Headquarter

    Brownsville, Texas

  • Velocity Clinical Research - Austin

    Cedar Park, Texas

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.